Human Immunology Core

项目摘要 自2005年以来一直由NCI批准的人类免疫学核心，提供最先进的 用于临床试验和免疫学研究的免疫分析、细胞产品和免疫学专业知识。 Core产生的免疫学数据被用来评估和改进新的癌症疗法。这个 CORE还提供样本和试剂，以促进基础研究和翻译研究，从而增强我们的 了解肿瘤微环境和宿主免疫反应。在项目期间， CORE已经支持了48项临床试验。设施主任，副教授伊莱恩(妮娜)鲁宁·普拉克博士 病理学和实验室医学博士，因其对基础B细胞免疫学的贡献和 作为一名专门从事临床免疫学检测的病理学家，她在翻译人类免疫学方面的领导地位 发展。技术总监Jean Boyer博士是细胞免疫评估方面的专家 疫苗和免疫疗法的反应，并监督经验丰富的工作人员。核心执行广泛的 细胞免疫学检测，包括细胞增殖检测、多功能淋巴细胞亚群检测 通过流式细胞术、Luminex和测量淋巴细胞激活和特异性的分析，包括 ELISPOT和细胞内细胞因子图谱。在卢宁·普拉克博士的领导下，核心扩大了其 在分子免疫学和高复杂性数据分析方面的服务，现在执行高吞吐量 抗体基因重排的测序、克隆和分析，TCR检测正在进行中。 服务还包括提供来自分离捐赠者的纯化的初级人体血细胞亚群，以及 带注释的标本处理和存储。核心工作人员与每个调查员密切合作，以执行 为每项研究和临床试验提供最佳的免疫学分析和样品处理。核心可以 根据需要，在试验性研究的基础上，或按照实验室良好做法的标准进行研究。从… 2013年10月1日至2014年9月30日，有49个ACC成员使用了核心服务。它们代表着 九个项目：乳腺癌，癌症控制，癌症治疗，血液恶性肿瘤， 免疫生物学、黑色素瘤和皮肤恶性肿瘤、儿科肿瘤学、肿瘤生物学和肿瘤 病毒学。具有同行评审资金的成员占核心总使用量的34%。CCSG支持 占拟议核心预算的10%，剩余资金来自按存储容量使用计费和 制度保障。

Project Summary The Human Immunology Core, which has been approved by the NCI since 2005, provides state-of-the-art immune assays, cellular products and immunological expertise for clinical trials and immunology research. Immunological data generated by the Core are used to evaluate and improve novel cancer therapies. The Core also provides specimens and reagents to facilitate basic and translational research that enhances our understanding of the tumor microenvironment and the host immune response. During the project period, the Core has supported 48 clinical trials. The Facility Director, Dr. Eline (Nina) Luning Prak, Associate Professor of Pathology and Laboratory Medicine, is recognized for her contributions to basic B cell immunology and for her leadership in translational human immunology as a pathologist specializing in clinical immunology assay development. The Technical Director, Dr. Jean Boyer, is an expert in the assessment of cellular immune responses to vaccines and immunotherapy, and oversees an experienced staff. The Core performs a wide range of cellular immunology assays including cell proliferation assays, multifunctional lymphocyte subset analysis by flow cytometry, luminex, and assays that measure lymphocyte activation and specificity, including ELISPOT and intracellular cytokine profiling. Under Dr. Luning Prak's leadership, the Core has expanded its services in molecular immunology and high complexity data analysis, and now performs high throughput sequencing, cloning and analysis of antibody gene rearrangements, with TCR assays in the pipeline. Services also include the provision of purified primary human blood cell subsets from apheresis donors, and annotated specimen handling and storage. The Core staff works closely with each investigator to perform the optimal immunological assays and sample processing for each research study and clinical trial. The Core can perform studies on a pilot research basis, or at the standard of Good Laboratory Practices, as needed. From October 1, 2013 through September 30, 2014, 49 ACC members have used Core services. They represent nine Programs: Breast Cancer, Cancer Control, Cancer Therapeutics, Hematologic Malignancies, Immunobiology, Melanoma and Cutaneous Malignancies, Pediatric Oncology, Tumor Biology and Tumor Virology. Members with peer-reviewed funding account for 34% of total Core usage. CCSG support represents 10% of the proposed Core budget with the remaining funding coming from charge backs and Institutional support.